isaralgagene civaparvovec vs pegunigalsidase alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Fabry Disease
Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline
isaralgagene civaparvovec
Developed by PTC Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
pegunigalsidase alfa
Marketed by Chiesi Farmaceutici and partners
NCT03566017 · Phase 3 · completed
This was a genuine open-label extension of studies PB-102-F03, PB-102-F20, and PB-102-F30, with 97 participants and 81 completing the extension, but it was single-arm and unblinded with no comparator. Its primary focus was treatment-related adverse events rather than a randomized clinical efficacy comparison, so the findings provide useful long-term safety and descriptive follow-up evidence but cannot establish comparative treatment benefit. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Treatment-related Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: October 2027 · NCT05710692 (registry estimate)
Reported efficacy
Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) (met)
Result source: NCT02795676
Results for Fabry Disease
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
isaralgagene civaparvovec: registry results are on file for Fabry Disease, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: isaralgagene civaparvovec's landscape · pegunigalsidase alfa's landscape